ClinicalTrials.gg
RecruitingNCT07229235REAL-CAREUpdated Jun 25, 2026

REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria

An observational study in Paroxysmal Nocturnal Hemoglobinuria (PNH), sponsored by Novartis Pharmaceuticals. Recruiting at 12 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
50
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Hemoglobinuria, Paroxysmal by Novartis — 5 open to participants now, 7 under way, 2 of them phase 3. Hemoglobinuria, Paroxysmal · Novartis.

Started
2026
with 1 other
Observational
7 of 16
4 open now
Registered
15th of 16
by date

Among the 16 studies in Hemoglobinuria, Paroxysmal by Novartis, this one is one of 2 that started in 2026, is one of 7 observational ones, and was the 15th registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 48 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

5 of the 16 studies in Hemoglobinuria, Paroxysmal by Novartis are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 29 Hemoglobinuria, Paroxysmal studies recruiting now, 13 (45%) set no upper age limit and 11 (38%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Hemoglobinuria, Paroxysmal by Novartis, or all of them as a file.
02

Study summary

This study evaluates iptacopan effectiveness and safety in routine clinical practice, with a focus on hematological response, transfusion avoidance, and patient-reported outcomes.

The primary objective of the REAL-CARE study is to is to assess the long-term hematological response following iptacopan initiation. This will be assessed through the absolute change in hemoglobin (Hb) levels at 12 months post-initiation, and the proportion of patients who remain free from red blood cell (RBC) transfusions, prescribed as per local requirement and based on Investigator's judgment, from Day 14 through Month 12 after starting iptacopan.

Read the detailed description

This is a local, multicenter, observational study with retrospective, retro-prospective and prospective cohorts. Adult patients with PNH either naïve to iptacopan or transitioning from the Managed Access Program (MAP) starting from January 2023 will be enrolled. Primary data will be collected prospectively; secondary data will be retrieved retrospectively from patients previously treated under MAP. A mix of primary and secondary data will be collected in retro-prospective patients. Patients will be indexed on the date of iptacopan initiation and will be followed up for 24 months or until iptacopan discontinuation (due to occurrence of an adverse event, lack of efficacy etc), clinical decision, death, administrative issues, consent withdrawal or loss to follow-up, whichever comes first. The enrollment period is planned to last 15 months, with potential adjustments based on enrollment progress. No treatment decision will be influenced by study participation.

No extra visits, examinations, or procedures are imposed. Questionnaires should be collected at the indicated timepoints whenever possible, but, since the administration of the questionnaires represents an additional procedure not included in routine clinical care, these timepoints are considered indicative only, and patients will not be recalled specifically to complete questionnaires if a routine clinical visit is not scheduled.

03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria (PNH)

Keywords

  • REAL-CARE
  • ptacopan
  • paroxysmal nocturnal hemoglobinuria
  • PNH
  • NIS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Italian population of adult patients with PNH either naïve to iptacopan or transitioning from the Managed Access Program (MAP) starting from January 2023

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. signed : patient must provide written informed before any study assessment is collected; in case of deceased patients, informed consent is not required as per Art. 110, comma 1 of Legislative Decree n° 196, dated 30 June 2003 as amended by D.lgs. 101/2018 and the "Autorizzazione generale al trattamento dei dati personali effettuato per scopi di ricerca scientifica" n° 9/2016
  2. Male and female,
  3. ≥ 18 years of age,
  4. documented diagnosis of PNH,
  5. followed in Italian clinical sites,
  6. on treatment with iptacopan prescribed as per routine medical care (i.e. patients naïve to treatment for whom the decision to start this treatment has already been made on the basis of clinical practice and according to SmPC and AIFA criteria and regardless of inclusion in this study or patients already treated under the Managed Access Program (MAP))

Exclusion criteria

Exclusion criteria:

1.Concomitant participation in an interventional clinical study related to PNH or its treatment.

No other inclusion/exclusion criteria apply other than the requirements stated in the Summary of Product Characteristics (SmPC).

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Iptacopan

    Treatment with iptacopan

06

What researchers measure

Primary outcomes

  1. absolute change in Hb level post iptacopan initiation

    12-month absolute change in hemoglobin (Hb) level post iptacopan initiation

    Time frame: 12 months

  2. Proportion of patients with no RBC transfusions

    12-month proportion of patients with no Red Blood Cells (RBC) transfusions, prescribed as per local requirement and based on Investigator's judgment, after Day 14.

    Time frame: 12 months

Secondary outcomes

  1. Socio-demographic and clinical variables of Paroxysmal Nocturnal Hemoglobinuria population

    Descriptive measures of the socio-demographic variables, proportion of PNH cells, clinical symptoms, laboratory parameters, concomitant diseases and treatments and outcomes of PNH patients at iptacopan initiation.

    Time frame: date of iptacopan start, day 0

  2. Absolute change in Hb level post iptacopan initiation

    24-month absolute change in Hb level post iptacopan initiation

    Time frame: date of iptacopan start (day 0), 24 months

  3. Proportion of patients who didn't need RBC transfusion

    24-month proportion of patients who didn't need RBC transfusion, prescribed as per local requirement and based on Investigator's judgment, post iptacopan initiation

    Time frame: 24 months

  4. Proportion of patients with Hb levels ≥ 12 g/dL AND no RBC transfusion

    12- and 24-month proportion of patients with Hb levels ≥ 12 g/dL AND no RBC transfusion, prescribed as per local requirement and based on Investigator's judgment, between Day 14 and month 12 or month 24

    Time frame: 12 month, 24 month

  5. Proportion of patients with change in Hb levels ≥ 2 g/dL post iptacopan initiation AND no RBC transfusion

    12- and 24-month proportion of patients with change in Hb levels ≥ 2 g/dL post iptacopan initiation AND no RBC transfusion, prescribed as per local requirement and based on Investigator's judgment, between Day 14 and month 12 or month 24

    Time frame: 12 month, 24 month

  6. Average number of RBC transfusion

    Average number of RBC transfusion, prescribed as per local requirement and based on Investigator's judgment, per patient during 12- and 24-months post iptacopan initiation

    Time frame: 12 months and 24 months

  7. Percentage change in LDH level post iptacopan initiation

    12- and 24-month percentage change in LDH level post iptacopan initiation.

    Time frame: date of iptacopan start (day 0), month 12, month 24

  8. Change in reticulocyte count post iptacopan initiation.

    12- and 24-month change in reticulocyte count post iptacopan initiation.

    Time frame: date of iptacopan start (day 0), month 12, month 24

  9. Absolute change in bilirubin level post iptacopan initiation.

    12- and 24-month absolute change in bilirubin level post iptacopan initiation.

    Time frame: date of iptacopan start (day 0), month 12, month 24

  10. Frequency of adverse events (AE) and serious adverse events (SAE) over 12 and 24 months of follow-up

    Frequency of adverse events (AE) and serious adverse events (SAE) over 12 and 24 months of follow-up post iptacopan initiation

    Time frame: 12 months and 24 months

  11. Proportion of BTH occurrence

    Proportion of Breakthrough Hemolysis (BTH) occurrence over 12 and 24 months of follow-up post iptacopan initiation

    Time frame: 12 months and 24 months

  12. Type and proportion of Infections occurrence over 12 and 24 months of follow-up

    Type and proportion (count and percentage) of Infections occurrence over 12 and 24 months of follow-up post iptacopan initiation

    Time frame: 12 months and 24 months

  13. Type and proportion of major adverse vascular events (MAVEs) occurrence

    Type and proportion of major adverse vascular events (MAVEs) occurrence over 12 and 24 months of follow-up post iptacopan initiation

    Time frame: 12 months and 24 months

  14. Type and proportion of new comorbidities

    Type and proportion of new comorbidities occurred within 12 and 24 months of follow-up post iptacopan initiation

    Time frame: 12 months and 24 months

  15. Type and proportion of concomitant medications newly prescribed

    Type and proportion of concomitant medications newly prescribed during 12 and 24 months of follow-up post iptacopan initiation

    Time frame: 12 months and 24 months

  16. Absolute change in Medication Adherence Report Scale - 5 item (MARS-5) scores

    The MARS-5 questionnaire is a validated self-report questionnaire developed to assess patient adherence to prescribed medication, focusing on both intentional and unintentional non-adherence. It consists of five items, each rated on a 5-point Likert Scale, from 0 ("Always") to 5 ("Never"). Items evaluate behaviors such as forgetting to take medications, altering the dose or stopping the treatment. The total score ranges from 5 to 25, with higher scores indicating better adherence to treatment.

    Time frame: date of iptacopan start (day 0), month 12 and month 24

  17. Absolute change from iptacopan initiation in PROMIS-29+2 score.

    The Patient-Reported Outcomes Measurement Information System (PROMIS) Profile-29+2 is a validated standardized patient reported outcome measure to assess generic health-related quality of life. The questionnaire covers the following nine health domains: Physical function, Anxiety, Depression, Fatigue, Sleep disturbance, Ability to participate in social roles and activities, Pain interference, Cognitive function and Pain intensity. The recall period for all items is the past 7 days. Each of the first eight domains is assessed through 4 items using a 5-point Likert scale. Pain intensity is measured with a single item on an 11-point numeric rating scale from 0 ("no pain") to 10 ("worst imaginable pain"). Each domain is scored separately, with T-scores used to represent the severity or level of functioning in each area. Higher scores can indicate either better health (e.g., physical function) or greater severity of symptoms (e.g., anxiety, depression).

    Time frame: date of iptacopan start (day 0), month 12 and month 24

  18. Absolute change from iptacopan initiation in WPAI:SHP score.

    Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) is a validated patient-reported outcome measure designed to assess the impact of a specific health problem on work and daily activities. In this study, the questionnaire has been customized for PNH. It includes six questions grouped into four key domains: Absenteeism (work time missed due to PNH), Presenteeism (impairment while working due to PNH), Overall work productivity loss (combined absenteeism and presenteeism), Activity impairment (impact of PNH on regular daily activities outside of work). The recall period is the past 7 days. Responses are used to calculate the percentage of work time missed and the level of impairment experienced by the patient. Higher scores represent greater impairment and reduced productivity.

    Time frame: date of iptacopan start (day 0), month 12 and month 24

  19. Number of hospitalizations, emergency room visits, and hospital-based outpatient visits attributable to the management of AEs related to the study treatment

    Healthcare resources utilization: The number of hospitalizations, emergency room visits, and hospital-based outpatient visits attributable to the management of adverse events (AEs) related to the study treatment will be documented.

    Time frame: Up to 24 months

07

Study locations

12 of 12 sites recruiting
  • Novartis Investigative Site
    Alessandria, AL 15121, Italy
    Recruiting
  • Novartis Investigative Site
    Avellino, AV 83100, Italy
    Recruiting
  • Novartis Investigative Site
    Brescia, BS 25123, Italy
    Recruiting
  • Novartis Investigative Site
    Florence, FI 50134, Italy
    Recruiting
  • Novartis Investigative Site
    Genova, GE 16132, Italy
    Recruiting
  • Novartis Investigative Site
    Milan, MI 20122, Italy
    Recruiting
  • Novartis Investigative Site
    Milan, MI 20132, Italy
    Recruiting
  • Novartis Investigative Site
    Palermo, PA 90146, Italy
    Recruiting
  • Novartis Investigative Site
    Roma, RM 00161, Italy
    Recruiting
  • Novartis Investigative Site
    Roma, RM 00168, Italy
    Recruiting
  • Novartis Investigative Site
    Torino, TO 10126, Italy
    Recruiting
  • Novartis Investigative Site
    Bassano del Grappa, VI 36061, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Aug 2028, 31 months after the start.

Of 23 observational studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 245. This study's planned 31 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2025
First posted
Nov 14, 2025
StartActual
Jan 13, 2026
Primary completionEst.
Aug 31, 2028
CompletionEst.
Aug 31, 2028
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07229235
Responsible party
Sponsor
First posted
Nov 14, 2025
Start date
Jan 13, 2026
Primary completion
Aug 31, 2028 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Jun 25, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
Novartis Pharmaceuticals
Contact
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion